Clinical Trials Round-Up: October 2020
by Mini Gill
Actively Recruiting Studies
Brain Cancer (Primary) – Glioma
Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265)
Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (NCT02796261)
PNI/JWCI: Precision Immunotherapy in Neoadjuvant Setting – A Longitudinal Assessment of Tumor Evolution in Patients with Brain Cancer (NCT03425292)
Non-Glioma
Northwestern: (PDF): A Phase 2, single arm, multi-center, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma (NCT02847559)
Chordoma – PNI/JWCI (PDF): Pilot Study of Pemetrexed for the Treatment of Chordoma (NCT03955042)
Solid Tumors
Bayer (PDF): ON-TRK: PrOspective Non-interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer treated with Larotrectinib (NCT03025360)
Incyte (PDF): A Phase 2, Open-Label Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations of Translocations (FIGHT-207) (NCT03822117)
Sanofi Aventis (PDF): A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination with Atezolizumab or Isatuximab Alone in Patients with Advanced Malignancies (NCT03463265)
Neurology
Bioness OAB (PDF): Pivotal Randomized Clinical Trial of Peripheral Nerve Stimulation with StimRouter Neuromodulation System in Overactive Bladder (NCT02873312)
Corcept (PDF): Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant (NCT03697109)
Prevention (PDF): Precision Recommendations for Environmental Variables, Exercise, Nutrition and Training Interventions to Optimize Neurocognition in those with a underlying Mild Alzheimer’s Disease (NCT04082611)
Quality and Outcomes Research
CancerLife2 (PDF): CancerLife: Patient-Driven Solution in Cancer Care (NCT03371147)
Family Caregivers (PDF): An Exploratory Study of Caregiver Burden Among Family Caregivers of Cancer Patients (NCT03069105)
Neurametrix (PDF): An Exploratory Study of Typing Cadence or Keystroke Dynamics as a Non-Invasive Approach to Measure Neurological Function
PNI/JWCI (PDF): An Observational Study of Memantine XR (extended release) and Pregabalin Combination Therapy in Chemotherapy-Induced Peripheral Neuropathy (CIPN) (NCT03709888)
PNI/JWCI (PDF): Feasibility and Acceptability of Integrating Family Caregiver Support into Cancer Clinical
PNI/JWCI (PDF): Neurological Outcomes in Health and Disease
Upcoming Trials
Brain Metastases – Blue Earth Diagnostics FLC 219: An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy (PURSUE)
Newly Diagnosed GBM – Trident EF-32: A Phase III Randomized, open-label study of Optune® (TTFields, 200KHZ) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma
Recurrent GBM – Theradex OKN-007: Phase II trial investigating the efficacy, safety, and pharmacokinetic properties of OKN-007 combined with TMZ in recurrent Glioblastoma multiforme patients (1st relapse)
Solid Tumor – Spectrum 107: An Open-label, Nonrandomized, Phase 1 Drug-Drug Interaction Study to Evaluate the Pharmacokinetics of Belinostat in Combination with Atazanavir in Patients with Advanced Relapsed/Refractory Solid Tumors or Hematological Malignancies
For more information, please contact the neurosciences Clinical Trials Team at:
E-mail: Neuro.Oncology@jwci.org or Neuro.Trials@pacificneuro.org
Phone: 310-829-8265
Investigators:
Clinical Trials Team:
Ashley Archer, CRA ArcherA@jwci.org 310-582-7460 | Delisa Madere, RA Delisa.Madere@providence.org |
Aarthi Ganapathi, CRA Aarthi.Ganapathi@providence.org 424-216-8269 | Raffi Nersesian, CRA Raffi.Nersesian@providence.org 310-829-8808 |
Annie Heng, RN, BSN Annie.Heng@providence.org 310-582-7457 | Hanh Nguyen, CRA NguyenThuyH@jwci.org 310-582-7434 |
Audrey Hiemer, RN Audrey.Hiemer@providence.org 310-582-7097 | Brittany Youssef, CRA Brittany.Youssef@providence.org |
Jack Hodes, CRA jhodes@pacificneuro.org | Gacia Tachejian, CRA Gacia.Tachejian@providence.org |
About the Author
Mini Gill
Jaya Mini Gill, RN, BSN is involved in all aspects of clinical trial study design and processes in the Department of Translational Neurosciences and Neurotherapeutics at the Saint John’s Cancer Institute. An experienced nurse, she is responsible for accurate protocol implementation along with the treatment, care, management, and follow-up of patients.
Last updated: February 23rd, 2021